The Efficacy and Safety of Teprotumumab in Geriatrics Patients: A Multicenter Study

医学 多中心研究 老年病科 不利影响 重症监护医学 疾病 急诊医学 保证 临床试验 纵向研究 儿科 梅德林 物理疗法 眼病 甲状腺 内科学 甲状腺疾病
作者
Shreya Shah,Patcharaporn Chandraparnik,Suyoung Choi,Linus Amarikwa,Ridhima Guniganti,Hannah L. Walsh,Rafael Rubio,Taylor J. Linaburg,Evan C. Meyer,Reem Karmouta,Connie Martin Sears,Melissa Goldin,Benyam Kinde,Chrysoula Dosiou,Amina I. Malik,Louise A. Mawn,Roman Shinder,Sara Tullis Wester,Daniel B. Rootman,Kimberly Peele Cockerham
出处
期刊:Ophthalmic Plastic and Reconstructive Surgery [Lippincott Williams & Wilkins]
卷期号:42 (1): 102-109 被引量:3
标识
DOI:10.1097/iop.0000000000003024
摘要

PURPOSE: To evaluate the efficacy and safety of teprotumumab for the treatment of thyroid eye disease in geriatric patients. METHODS: This was a multicenter cohort study of patients aged 75 and older, treated between February 2020 and September 2023 across 10 tertiary institutions. Patients were included if they had moderate-to-severe thyroid eye disease and at least 1 infusion of teprotumumab. Efficacy outcome measures included improvement in clinical activity score, proptosis, and Gorman diplopia score. Safety outcome measures included teprotumumab-related adverse event (TAE) incidence, onset, and severity. RESULTS: Fifty patients (40 females, 10 males), average age of 79.2 years, were evaluated. Patients received an average of 6.9 infusions, with 34.0% (17/50) discontinuing treatment due to TAEs. Mean baseline clinical activity score was 4.0 ± 1.6, with a mean reduction of 4.0 ± 1.1. Proptosis improved by ≥2 mm in 86.0% (43/50) of patients, with a mean reduction of 4.24 mm. Of patients with baseline diplopia, 42.9% (18/42) experienced an improvement in Gorman diplopia score. Proptosis regression occurred in 62.5% (15/24) of patients at 2.5 years, and 27.9% (12/43) experienced thyroid eye disease reactivation on average 49.8 weeks posttreatment completion. TAEs were reported by 78.0% (39/50) of patients, with 30% (15/46) experiencing moderate TAEs and 14% (7/50) severe TAEs. The most common TAEs were muscle cramps (42.0%, 21/50), hearing impairment (38.0%, 19/46), and hyperglycemia (36.0%, 18/46). CONCLUSIONS: Teprotumumab is effective in reducing clinical activity score and proptosis in geriatric thyroid eye disease patients with short-term follow-up; however, high rates of adverse events, reactivation, and proptosis regression over time warrant extreme caution and selective use in this population.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2316690509完成签到 ,获得积分10
1秒前
3秒前
wangyiyang0604完成签到 ,获得积分10
4秒前
春夏完成签到 ,获得积分10
4秒前
6秒前
秀丽若魔完成签到,获得积分10
6秒前
10秒前
陈淋完成签到,获得积分10
12秒前
研友_nPkKEL发布了新的文献求助10
13秒前
汉堡包的应助被季末默相依采纳,获得10
15秒前
滴滴答答发布了新的文献求助10
15秒前
Baonanza完成签到,获得积分10
16秒前
tina完成签到,获得积分10
21秒前
Lrcx完成签到 ,获得积分10
28秒前
涩费爱完成签到 ,获得积分10
29秒前
无限的丸子曾完成签到 ,获得积分10
30秒前
苗条的巧凡完成签到,获得积分10
34秒前
XiaohuaTu完成签到 ,获得积分10
34秒前
35秒前
假真真完成签到 ,获得积分10
36秒前
清淮完成签到 ,获得积分10
36秒前
夏安完成签到,获得积分10
36秒前
柿子完成签到,获得积分10
38秒前
悦耳的保温杯完成签到 ,获得积分10
41秒前
淮安石河子完成签到 ,获得积分10
42秒前
42秒前
水water完成签到 ,获得积分10
43秒前
43秒前
waveless完成签到,获得积分10
44秒前
yy完成签到,获得积分10
45秒前
zhangnan完成签到 ,获得积分10
45秒前
Sweet完成签到 ,获得积分10
47秒前
愛愛愛愛完成签到,获得积分10
47秒前
tanjuan发布了新的文献求助10
49秒前
彳亍宣完成签到 ,获得积分10
51秒前
嗡嗡声完成签到 ,获得积分10
54秒前
55秒前
茄子回锅肉完成签到,获得积分10
56秒前
姚怜南完成签到,获得积分10
57秒前
忧心的藏鸟完成签到 ,获得积分10
57秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180084
求助须知:如何正确求助?哪些是违规求助? 9570224
关于积分的说明 21808758
捐赠科研通 7776098
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557454
邀请新用户注册赠送积分活动 2479012